Avivagen Announces Second Closing of Private Placement
14 Novembro 2013 - 12:10PM
Access Wire
OTTAWA, ONTARIO, November 14, 2013 - Avivagen
Inc. (TSXV:VIV), a wellness company developing and delivering
products that support and enhance the health and quality of life
for animals and the people who care for them, announces a second
closing of its previously announced private placement.
"Avivagen believes that a strong balance sheet will assist in
securing global development, marketing and distribution
arrangements for our products: Potential business partners need to
know that Avivagen can follow-through on its commitments." stated
C.E.O. & President Cameron Groome. "Combining the amount raised
in our first closing in October with this second closing, Avivagen
has raised a total of 3.42 million dollars - more than double our
minimum targeted amount. We now look forward to realizing our major
corporate objectives." concluded Mr. Groome.
The private placement second closing of $1,345,747.97 was
comprised of the sale of 19,224,971 units with each
unit being comprised of one common share and one-half of a common
share purchase warrant, for a unit price of $0.07. Each whole
warrant entitles the holder to acquire one common share of Avivagen
at an additional purchase price of $0.12 for three years from
closing.
Avivagen paid a total of $55,387.40 in cash and issued a total
of 1,582,497 common share purchase warrants to finders in
connection with the private placement. Each finders' warrant is
exercisable into one common share of the Company for a period of
two years at a price of $0.10 per share.
All securities issued via this placement are subject to
statutory hold period expiring on March 14, 2014. The
private placement remains subject to TSX Venture Exchange
approval.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company
trading on the TSX Venture Exchange under the ticker
symbol "VIV". The Company's goal is to develop and deliver
scientifically-proven solutions that can truly benefit companion
and production animals by employing natural mechanisms for
maintaining good health. Avivagen's targeted markets include Pet
Wellness and Livestock Productivity.
The company has sites located in partnership facilities of
the National Research Council of Canada (NRC) - in Ottawa, Ontario
and Charlottetown, Prince Edward Island. More
information can be found at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected
technology is based on its discoveries concerning carotenoid
antioxidants. The novel natural compounds discovered by Avivagen
support the body's own systems to maintain and enhance health,
particularly by supporting immune function. Avivagen's
commercial-stage application of its technology is Fully-Oxidized
beta-Carotene (OxC-beta). OxC-beta compounds occur naturally as
carotenoid oxidation products in vegetation, but in minute amounts.
They have been developed to support the health of companion animals
and for use in the global food animal market.
Research results indicate OxC-beta supports innate immune
function, which can help maintain good health. In pets, OxC-beta
supports overall vitality and energy, mobility and joint function,
skin, coat and gut. Results observed in food animals have included
healthier growth, better utilization of feed and decreased
mortality. In food animals, it is intended that use of OxC-beta
avoids the feeding of antibiotics.
The commercial products of Avivagen are
Oximunol(TM) Chewables, OxC-beta for livestock and
Vivamune(TM) Health Chews.
About
Vivamune(TM) Health Chews -
"For dogs that dig life" and "For extraordinary cats"
Vivamune(TM) Health Chews, containing
Avivagen's proprietary active ingredients, are
scientifically-formulated chews for dogs and cats. Vivamune(TM)
Health Chews work with a pet's own immune system to maintain
overall health and well-being. They are sold in re-sealable
packages of 30 chews and are currently available in the United
States by ordering on-line at www.vivamunehealth.com.
About Oximunol(TM) Chewables -
"Optimized Health in a Chewable Tablet"
Oximunol(TM) Chewables are
scientifically-formulated chewable tablets that contain Avivagen's
proprietary, patented active ingredient OxC-beta. OxC-beta has been
shown to stimulate innate cellular immunity and may thereby help to
maintain overall health and well-being. Oximunol(TM) Chewables are
distributed by Bayer Healthcare LLC and are available through
veterinarians for dogs of all ages in the United States.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0
or 5.0 Kg quantities for parts-per-million addition to animal
feeds, in accordance with producer-developed protocols. In past
studies, OxC-beta has been shown to support health and growth in
species such as fish, chicken, pigs and cattle. OxC-beta for
livestock is currently available for commercial sale in the Kingdom
of Thailand.
Forward Looking
Statements
This news release
includes certain forward-looking statements that are based upon
current expectations, which involve risks and uncertainties
associated with the business of Avivagen Inc. and the environment
in which the business operates. Any statements contained herein
that are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions
"will", "anticipate", "believe", "plan", "estimate", "expect",
"intend", and similar expressions. The forward-looking statements
reflect the current expectations of Avivagen Inc. regarding future
results or events. These forward-looking statements are subject to
a number of risks and uncertainties that could cause actual results
or events to differ materially from current expectations. Avivagen
assumes no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
reflected in the forward-looking statements.
Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
For more
information:
Avivagen Inc.
Cameron Groome
CEO & President
Phone: 613-949-8164
c.groome@avivagen.com
Avivagen (TSXV:VIV)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Avivagen (TSXV:VIV)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024